| Total number of patients (n = 258) | CLL (n = 215) | MBL (n = 43) |
| Males, n (%) | 120 (55.8) | 14 (32.6) |
| Median age (range), y | 72 (22-95) | 72 (49-88) |
| Median age at diagnosis (range), y | 60 (18-85) | 67.5 (27-84) |
| Seroconversion (at the time of analysis) | ||
| Positive, n (%) | 180 (94.2) | 43 (100) |
| Negative, n (%) | 11 (5.8) | 0 (0) |
| Lost contact, n | 24 | 0 |
| Cytogenetics | ||
| Del 13q, n (%) | 92/145 (63.4) | 6/10 (60) |
| Del 11q, n (%) | 16/145 (11) | 0/10 (0) |
| Del 17p, n (%) | 10/145 (6.9) | 0/10 (0) |
| Trisomy 12, n (%) | 23/145 (15.9) | 1/10 (10) |
| Unknown, n | 70 | 36 |
| IGHV, n | ||
| Mutated | 27 | — |
| Unmutated | 7 | — |
| Unknown | 181 | 43 |
| Treatment status at vaccination, n (%) | ||
| Treatment naïve | 119 (55.3) | 43 (100) |
| Off therapy in remission (complete or partial remission) | 46 (21.4) | 0 (0) |
| Off therapy in relapse | 6 (2.8) | 0 (0) |
| On therapy | 44 (20.5) | 0 (0) |
| Immunoglobulin replacement therapy, n (%) | ||
| Currently on | 27 (12.6) | 0 (0) |
| Prior but not current | 10 (4.7) | 0 (0) |
| Never on immunoglobulin replacement therapy | 149 (69.3) | 43 (100) |
| Unknown | 29 (13.5) | — |
| Anti-CD20 inhibitor in the last 12 mo, n (%) | ||
| Yes | 14 (6.5) | 0 (0) |
| No | 201 (93.5) | 43 (100) |
| Total number of patients (n = 258) | CLL (n = 215) | MBL (n = 43) |
| Males, n (%) | 120 (55.8) | 14 (32.6) |
| Median age (range), y | 72 (22-95) | 72 (49-88) |
| Median age at diagnosis (range), y | 60 (18-85) | 67.5 (27-84) |
| Seroconversion (at the time of analysis) | ||
| Positive, n (%) | 180 (94.2) | 43 (100) |
| Negative, n (%) | 11 (5.8) | 0 (0) |
| Lost contact, n | 24 | 0 |
| Cytogenetics | ||
| Del 13q, n (%) | 92/145 (63.4) | 6/10 (60) |
| Del 11q, n (%) | 16/145 (11) | 0/10 (0) |
| Del 17p, n (%) | 10/145 (6.9) | 0/10 (0) |
| Trisomy 12, n (%) | 23/145 (15.9) | 1/10 (10) |
| Unknown, n | 70 | 36 |
| IGHV, n | ||
| Mutated | 27 | — |
| Unmutated | 7 | — |
| Unknown | 181 | 43 |
| Treatment status at vaccination, n (%) | ||
| Treatment naïve | 119 (55.3) | 43 (100) |
| Off therapy in remission (complete or partial remission) | 46 (21.4) | 0 (0) |
| Off therapy in relapse | 6 (2.8) | 0 (0) |
| On therapy | 44 (20.5) | 0 (0) |
| Immunoglobulin replacement therapy, n (%) | ||
| Currently on | 27 (12.6) | 0 (0) |
| Prior but not current | 10 (4.7) | 0 (0) |
| Never on immunoglobulin replacement therapy | 149 (69.3) | 43 (100) |
| Unknown | 29 (13.5) | — |
| Anti-CD20 inhibitor in the last 12 mo, n (%) | ||
| Yes | 14 (6.5) | 0 (0) |
| No | 201 (93.5) | 43 (100) |